Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Buti

Showing results (41-50 of 386) with videos related to

Pageof 39
Sort By:
Journal of Hepatology|June 14, 2021
Anti-epileptic drugs and hepatitis C therapy: Real-world experienceCristina Marcos-Fosch, Joaquín Cabezas, Javier Crespo, et al.
Journal of Hepatology|December 20, 2005
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patientsMaria Buti, John Wong, Miguel Angel Casado, et al.
Pharmacoeconomics|October 21, 2005
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1Maria Buti, Miguel A Casado, Leslie Fosbrook, et al.
Hepatology (Baltimore, Md.)|January 24, 2003
Applicability of real-time PCR combined with melting curve analysis for the study of hepatitis B virus genome mutationsFrancisco Rodriguez-Frias, Rosendo Jardi, Maria Buti, et al.
World Journal of Gastroenterology|November 14, 2013
Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approachFrancisco Rodriguez-Frias, Maria Buti, David Tabernero, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analoguesMaria Buti, Luisa Roade, Mar Riveiro-Barciela, et al.
Therapeutic Advances in Infectious Disease|February 22, 2021
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis BLuisa Roade, Mar Riveiro-Barciela, Rafael Esteban, et al.
Medicina Clinica|August 30, 2022
[Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission]Pere Ginès, Maria Buti, Jeffrey V Lazarus, et al.
Journal of Hepatology|April 1, 2023
The pressing need for a global HEV vaccineJean-Marie Peron, Hélène Larrue, Jacques Izopet, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 8, 2006
Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypesMaria Buti, Francisco Rodriguez-Frias, Rosendo Jardi, et al.
Pageof 39

Showing results (41-50 of 386) with videos related to

Sort By:
Pageof 39
Journal of Hepatology|June 14, 2021
Anti-epileptic drugs and hepatitis C therapy: Real-world experienceCristina Marcos-Fosch, Joaquín Cabezas, Javier Crespo, et al.
Journal of Hepatology|December 20, 2005
Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patientsMaria Buti, John Wong, Miguel Angel Casado, et al.
Pharmacoeconomics|October 21, 2005
Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1Maria Buti, Miguel A Casado, Leslie Fosbrook, et al.
Hepatology (Baltimore, Md.)|January 24, 2003
Applicability of real-time PCR combined with melting curve analysis for the study of hepatitis B virus genome mutationsFrancisco Rodriguez-Frias, Rosendo Jardi, Maria Buti, et al.
World Journal of Gastroenterology|November 14, 2013
Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approachFrancisco Rodriguez-Frias, Maria Buti, David Tabernero, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 21, 2020
Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analoguesMaria Buti, Luisa Roade, Mar Riveiro-Barciela, et al.
Therapeutic Advances in Infectious Disease|February 22, 2021
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis BLuisa Roade, Mar Riveiro-Barciela, Rafael Esteban, et al.
Medicina Clinica|August 30, 2022
[Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission]Pere Ginès, Maria Buti, Jeffrey V Lazarus, et al.
Journal of Hepatology|April 1, 2023
The pressing need for a global HEV vaccineJean-Marie Peron, Hélène Larrue, Jacques Izopet, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 8, 2006
Hepatitis B virus genome variability and disease progression: the impact of pre-core mutants and HBV genotypesMaria Buti, Francisco Rodriguez-Frias, Rosendo Jardi, et al.
Pageof 39